Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey

Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey

ObjectiveTo survey barriers in prescribing naltrexone for alcohol use disorder.MethodsA 12-question survey related to naltrexone prescribing patterns, perceptions, and knowledge was sent to 770 prescribers in the departments of internal medicine, family medicine, and psychiatry across a health syste...

Full description

Bibliographic Details
Main Authors:	Jonathan G. Leung, Prasanna P. Narayanan, Matej Markota, Nathaniel E. Miller, Kemuel L. Philbrick, M. Caroline Burton, Robert W. Kirchoff
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Psychiatry
Subjects:	alcohol use disorder naltrexone prescribing substance use disorder survey
Online Access:	https://www.frontiersin.org/articles/10.3389/fpsyt.2022.856938/full

Similar Items

Naltrexone Implant for Opioid Use Disorder
by: Amber N. Edinoff, et al.
Published: (2021-12-01)

Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report
by: Laura M. Szczesniak, et al.
Published: (2020-10-01)

Prescribers’ satisfaction with delivering medications for opioid use disorder
by: Hannah K. Knudsen, et al.
Published: (2021-10-01)

Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review
by: Negin Farhadian, et al.
Published: (2020-03-01)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
by: Melissa Velasquez, et al.
Published: (2019-10-01)

Feasibility, Acceptability, and Preliminary Outcomes of an Integrated Telemedicine Intervention Combining Naltrexone and Cognitive Behavioral Therapy for Alcohol Use Disorder
by: Suzette Glasner, et al.
Published: (2022-11-01)

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis
by: Monica Bolton, et al.
Published: (2019-01-01)

Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates
by: Dale Terasaki, et al.
Published: (2022-11-01)

Comparison of the risk of drop-out from opioid maintenance treatment in patients using naltrexone implants vs. oral buprenorphine-naloxone (tur)
by: Umut Kırlı, et al.
Published: (2021-09-01)

Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Single Center Pilot Study
by: Sabrina Snyder, et al.
Published: (2024-02-01)

Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study)
by: Kirsten C. Morley, et al.
Published: (2018-08-01)

Systematic Analysis of the Service Process and the Legislative and Regulatory Environment for a Pharmacist-Provided Naltrexone Injection Service in Wisconsin
by: James H. Ford, et al.
Published: (2019-06-01)

The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia
by: Daniel Jackson, et al.
Published: (2021-02-01)

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
by: Kim A. Hoffman, et al.
Published: (2021-11-01)

Thyroid Function of Former Opioid Addicts on Naltrexone Treatment
by: Ioannis Ilias, et al.
Published: (2001-01-01)

A Case Report of a Dual Diagnosis Patient: Naltrexone for the Treatment of Severe Nitrous Oxide Use Disorder with Associated Neurological and Psychiatric Sequelae
by: Paige Juliet Staudenmaier, et al.
Published: (2023-02-01)

The Study of the Demographic and Clinical and Laboratory Findings in Naltrexone Poisoning Patients Admitted to Razi Hospital, Rasht, During 2007-08
by: Morteza Rahbar Taromsar, et al.
Published: (2012-08-01)

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
by: Anne Marciuch, et al.
Published: (2022-07-01)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
by: R. R. Cook, et al.
Published: (2023-02-01)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
by: Anne Marciuch, et al.
Published: (2023-07-01)

Services Available at United States Addiction Treatment Facilities That Offer Medications versus Behavioral Treatment Only: A Cross-Sectional, Observational Analysis
by: Weber A, et al.
Published: (2022-09-01)

Pharmacogenetics of alcohol addiction: current perspectives
by: Zastrozhin MS, et al.
Published: (2019-07-01)

Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
by: Matisyahu Shulman, et al.
Published: (2021-03-01)

Acute Myocardial Infarction following Naltrexone Consumption; a Case Report
by: Bita Dadpour, et al.
Published: (2016-12-01)

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
by: Marianna Ciwun, et al.
Published: (2024-03-01)

Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems
by: Sarah M. Bagley, et al.
Published: (2021-07-01)

Use of clonidine-naltrexone for rapid withdrawal in two patients dependent on intravenous morphine
by: Raveen Hanwella, et al.
Published: (2012-02-01)

Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs
by: Jaclyn M. W. Hughto, et al.
Published: (2023-05-01)

Veteran adherence to oral versus injectable AUD medication treatment
by: Hayden Stewart, PharmD, et al.
Published: (2021-05-01)

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review
by: Colleen G. Jordan, et al.
Published: (2022-04-01)

The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review
by: Yang J, et al.
Published: (2023-03-01)

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
by: Karlo Toljan, et al.
Published: (2018-09-01)

The Potential Role of Naltrexone in Borderline Personality Disorder
by: Azadeh Moghaddas, et al.
Published: (2017-04-01)

Precipitated withdrawal with kratom use following naltrexone administration
by: Jarka Courtney PharmD, BCPS, BCPP, et al.
Published: (2023-06-01)

Survey of noncontrolled medication misuse patterns
by: Amelia Slane, PharmD, et al.
Published: (2022-06-01)

The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study
by: Elizabeth C. Saunders, et al.
Published: (2022-12-01)

Treatment of repeated self- injurious behaviour with naltrexone: a case report
by: Praveen Navkhare, et al.
Published: (2013-12-01)

The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study
by: Lara Ray, et al.
Published: (2010-10-01)

A Structural Barrier to Healthcare: Stigma of Alcohol and Substance Use Disorders Among Health Care Workers
by: İ.G. Yilmaz-Karaman, et al.
Published: (2022-06-01)

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa–associated refractory pruritus
by: Lauren C. LaMonica, MPH, et al.
Published: (2023-08-01)